|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Preferential Attachment of Peritoneal Tumor Metastases to Omental Immune Aggregates and Possible Role of a Unique Vascular Microenvironment in Metastatic Survival and Growth显示文摘 | Scott A. Gerber Viktoriya Y. Rybalko Chad E. Bigelow Amit A. Lugade Thomas H. Foster John G. Frelinger Edith M. Lord | 2006 | The American Journal of Pathology2006，，5： | 2 |
| 2 | Measur- ing antiplatelet drug effects in the laboratory显示文摘 | Harrison P Frelinger AL 3rd FurmanMI | 2007 | Thromb Res2007，120，3： | 1 |
| 3 | Combination gene therapy with CD86 and the MHC class Ⅱtransactivator in the control of lung tumor growth显示文摘 | Martin BK Frelinger JG Ting JP | 1999 | J Immunol1999，162，11： | 1 |
| 4 | Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump in- hibitors) , and pre-existent variability in platelet func- tion显示文摘 | Frelinger AL Bhatt DL Lee RD | 2013 | J Am Coll Cardiol2013，61，8： | 1 |
| 5 | Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms(CYP2C19,ABCB1,PON1),noncompliance,diet,smoking,co-medications(including proton pump inhibitors),and pre-existent variability in platelet function显示文摘 | FRELINGER AL BHATT DL LEE RD | 2013 | J Am Coll Cardiol2013，61，8： | 1 |
| 6 | Mouse genetic lo cus Lps influences susceptibility to Neisseria meningitidis in fection显示文摘 | Woods J P Frelinger J A Warrack G | 1988 | Infect Immun1988，56，19： | 1 |
| 7 | Current options in platelet function testing显示文摘 | Miehelson AD Frelinger AL 3rd Furman MI | 2006 | Am J Cardio 12006，98，10： | 1 |
| 8 | Global Osteitis Scoring Scale and chronic rhinosinusitis:a marker of revision surgery显示文摘 | Georgalas C Videler W Freling N | | 0，，06： | 1 |
| 9 | Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease显示文摘 | MEGA J L HOCHHOLZER W FRELINGER A L | 2011 | JAMA2011，306，20： | 1 |
| 10 | Measuring antiplateletdrug effects in the laboratory显示文摘 | Harrison P Frelinger AL 3rd Furman MI eta 1 | 2007 | Thromb Res2007，120，： | 1 |
| 11 | Current options in platelet function testing显示文摘 | Michelson AD Frelinger AL 3rd Furman MI | 2006 | Am J Cardiol2006，98，10： | 1 |
| 12 | Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo显示文摘 | Mitra S Goren EM Frelinger JG | 2003 | Photochem Photobiol2003，78，6： | 1 |
| 13 | Current op-tions in platelet function testing显示文摘 | Michelson AD Frelinger AL Furman MI | 2006 | Am J Cardiol2006，98，10： | 1 |
| 14 | Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclo- oxygenase-l-and cyclooxygenase-2-independent path- way : a 700-patient study of aspirin resistance 显示文摘 | Frelinger AL 3rd Furman MI Linden MD | 2006 | Circulation2006，113，25： | 1 |
| 15 | Prasugrel com pared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Th rombolysis in Myo cardial Infarction 44 trial显示文摘 | Wiviott S D Trenk D Frelinger A L etal | 2007 | Circulation2007，116，25： | 1 |
| 16 | Application of flow cytometry to platelet disorders 显示文摘 | Linden MD Frelinger AL Barnard MR | 2004 | Semin Thromb Hemost2004，30，5： | 1 |
| 17 | Malignant parotid tumors:clinical use of MR imaging and histologic correlation显示文摘 | Freling NJ Molenaar WM Vermey A | | 0，，03： | 1 |
| 18 | Prasugrel compared with high loading- and maintenance-dose clopid0grel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelct activation and aggregation-thrombolysis in myocardial infarction 44 trial 显示文摘 | WIVIOTT SD TRENK D FRELINGER AL | 2007 | Circulation2007，116，25： | 1 |
| 19 | Prasugrel compared with high loading-and maintenance-dose elopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial显示文摘 | WIVIOTT SD TRENK D FRELINGER AL | 2007 | Circulation2007，116，25： | 1 |
| 20 | Dosing clopidogrel basedon CYP2C 19genotype and the effect on platelet reactivity in patients with stable cardiovascular disease 显示文摘 | MegaJL1 Hochholzer W: Frelinger AL | 2011 | Jama2011，306，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员